Summary:
- This article discusses a new post-hoc analysis from the HELIOS-B Phase 3 study, which showed that the drug vutrisiran improved measures of heart structure and function in patients with ATTR-CM (transthyretin amyloid cardiomyopathy).
- ATTR-CM is a rare and serious condition where abnormal proteins build up in the heart, leading to heart failure. The study found that vutrisiran helped reduce the thickening of the heart wall and improve the heart's ability to pump blood effectively.
- These findings suggest that vutrisiran could be a promising treatment option for patients with ATTR-CM, as it may help manage the symptoms and progression of this debilitating disease.